Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy - PubMed (original) (raw)

Case Reports

Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy

Luana Benedetti et al. Arch Neurol. 2007 Oct.

Abstract

Objective: To describe the unique case of a patient with multiple sclerosis (MS) and anti-myelin-associated glycoprotein (MAG) polyneuropathy who developed MS relapses after treatment with rituximab.

Design: Case report.

Setting: Department of Neurosciences, Ophthalmology, and Genetics, University of Genova, Genova, Italy. Patient A 59-year-old man with an 18-year history of MS presented with an unusually rapid progression of paraparesis with hypopallesthesia and areflexia in 4 limbs. Neurophysiological and serological studies led to the diagnosis of anti-MAG polyneuropathy. Cerebrospinal fluid analysis disclosed the loss of oligoclonal IgG bands that were previously detected at MS onset. Intervention Rituximab was administered at a dosage of 375 mg/m(2)/wk for 4 weeks. Result The patient developed 2 corticosteroid-responsive MS relapses with improvement of the polyneuropathy.

Conclusion: Rituximab can be effective in anti-MAG polyneuropathy but can possibly lead to unexpected consequences in individuals with MS.

PubMed Disclaimer

Similar articles

• High-dose rituximab and anti-MAG-associated polyneuropathy.
  Renaud S, Fuhr P, Gregor M, Schweikert K, Lorenz D, Daniels C, Deuschl G, Gratwohl A, Steck AJ. Renaud S, et al. Neurology. 2006 Mar 14;66(5):742-4. doi: 10.1212/01.wnl.0000201193.00382.b3. Neurology. 2006. PMID: 16534115 Clinical Trial.
• Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.
  Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwohl A, Steck AJ. Renaud S, et al. Muscle Nerve. 2003 May;27(5):611-5. doi: 10.1002/mus.10359. Muscle Nerve. 2003. PMID: 12707982 Clinical Trial.
• Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
  Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B. Dalakas MC, et al. Ann Neurol. 2009 Mar;65(3):286-93. doi: 10.1002/ana.21577. Ann Neurol. 2009. PMID: 19334068 Clinical Trial.
• Antibody-associated polyneuropathy syndromes: principles and treatment.
  Kornberg AJ, Pestronk A. Kornberg AJ, et al. Semin Neurol. 2003 Jun;23(2):181-90. doi: 10.1055/s-2003-41131. Semin Neurol. 2003. PMID: 12894383 Review.
• Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies.
  Vallat JM, Magy L, Ciron J, Corcia P, Le Masson G, Mathis S. Vallat JM, et al. Expert Rev Neurother. 2016 Sep;16(9):1111-9. doi: 10.1080/14737175.2016.1198257. Epub 2016 Jun 16. Expert Rev Neurother. 2016. PMID: 27267749 Review.

Cited by

• Spinal Cord Impairment in Anti-Mag Neuropathy: Evidence from Somatosensory Evoked Potentials.
  Boscarino M, Lanzone J, Ricci L, Tombini M, Di Lazzaro V, Assenza G. Boscarino M, et al. Brain Sci. 2020 May 8;10(5):282. doi: 10.3390/brainsci10050282. Brain Sci. 2020. PMID: 32397154 Free PMC article.
• Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.
  Lehmann-Horn K, Kinzel S, Weber MS. Lehmann-Horn K, et al. Int J Mol Sci. 2017 Sep 23;18(10):2048. doi: 10.3390/ijms18102048. Int J Mol Sci. 2017. PMID: 28946620 Free PMC article. Review.
• Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.
  Davis LS, Reimold AM. Davis LS, et al. Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i100-i113. doi: 10.1093/rheumatology/kew417. Rheumatology (Oxford). 2017. PMID: 28375452 Free PMC article. Review.
• Potential importance of B cells in aging and aging-associated neurodegenerative diseases.
  Biragyn A, Aliseychik M, Rogaev E. Biragyn A, et al. Semin Immunopathol. 2017 Apr;39(3):283-294. doi: 10.1007/s00281-016-0615-8. Epub 2017 Jan 12. Semin Immunopathol. 2017. PMID: 28083646 Free PMC article. Review.
• B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
  Kinzel S, Weber MS. Kinzel S, et al. CNS Drugs. 2016 Dec;30(12):1137-1148. doi: 10.1007/s40263-016-0396-6. CNS Drugs. 2016. PMID: 27844213 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program